Terms: = Kidney tumors AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
657 results:
1. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
[TBL] [Abstract] [Full Text] [Related]
2. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications.
Li J; Zhang L; Ge T; Liu J; Wang C; Yu Q
Drug Des Devel Ther; 2024; 18():829-843. PubMed ID: 38524877
[TBL] [Abstract] [Full Text] [Related]
3. Recent development of vegfr small molecule inhibitors as anticancer agents: A patent review (2021-2023).
Zeng J; Deng Q; Chen Z; Yan S; Dong Q; Zhang Y; Cui Y; Li L; He Y; Shi J
Bioorg Chem; 2024 May; 146():107278. PubMed ID: 38484586
[TBL] [Abstract] [Full Text] [Related]
4. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract] [Full Text] [Related]
5. Downregulation of praja2 restrains endocytosis and boosts tyrosine kinase receptors in kidney cancer.
Rinaldi L; Chiuso F; Senatore E; Borzacchiello D; Lignitto L; Iannucci R; Donne RD; Fuggi M; Reale C; Russo F; Russo NA; Giurato G; Rizzo F; Sellitto A; Santangelo M; De Biase D; Paciello O; D'Ambrosio C; Amente S; Garbi C; Dalla E; Scaloni A; Weisz A; Ambrosino C; Insabato L; Feliciello A
Commun Biol; 2024 Feb; 7(1):208. PubMed ID: 38379085
[TBL] [Abstract] [Full Text] [Related]
6. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract] [Full Text] [Related]
7. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over vegfr/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.
Tao J; Cui J; Xu Y; Fan Y; Hong G; Zhou Q; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Zhang X
Aging (Albany NY); 2024 Jan; 16(3):2090-2122. PubMed ID: 38301040
[No Abstract] [Full Text] [Related]
8. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
9. Leveraging diverse cell-death related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma.
Wu Z; Jin M; Xin P; Zhang H
Front Immunol; 2023; 14():1293729. PubMed ID: 38146369
[TBL] [Abstract] [Full Text] [Related]
10. Hereditary papillary renal cell carcinoma.
Jacoba IM; Lu Z
Semin Diagn Pathol; 2024 Jan; 41(1):28-31. PubMed ID: 38135585
[TBL] [Abstract] [Full Text] [Related]
11. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Hahn AW; Surasi DS; Viscuse PV; Bathala TK; Wiele AJ; Campbell MT; Zurita AJ; Shah AY; Jonasch E; Gao J; Goswami S; Alhalabi O; Rao P; Sircar K; Tannir NM; Msaouel P
Oncologist; 2024 May; 29(5):392-399. PubMed ID: 38035767
[TBL] [Abstract] [Full Text] [Related]
12. Acute heart failure following pazopanib treatment: a literature review featuring two case reports.
Kertmen N; Kavgaci G; Yildirim HC; Dizdar O
Anticancer Drugs; 2024 Mar; 35(3):302-304. PubMed ID: 38018812
[TBL] [Abstract] [Full Text] [Related]
13. [The Treatment of Metastatic Renal Cell Carcinoma: An Update].
Pezzicoli G; Ganini C; Re Sartò GV; Pirovano M; Cosmai L; Porta C
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007832
[TBL] [Abstract] [Full Text] [Related]
14. BR55 Ultrasound Molecular Imaging of Clear Cell Renal Cell Carcinoma Reflects Tumor Vascular Expression of vegfr-2 in a Patient-Derived Xenograft Model.
Courcier J; Leguerney I; Benatsou B; Pochon S; Tardy I; Albiges L; Cournède PH; De La Taille A; Lassau N; Ingels A
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003400
[TBL] [Abstract] [Full Text] [Related]
15. kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
[TBL] [Abstract] [Full Text] [Related]
16. Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
Schuster J; Sheng IY; Reddy CA; Khorana AA; Nizam A; Gupta S; Gilligan T; Wee CE; Sussman TA; Bonham A; Maroli K; Martin A; Ornstein MC
Clin Genitourin Cancer; 2024 Apr; 22(2):92-97. PubMed ID: 37932205
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
18. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Choueiri TK; Powles T; Voss MH; Plimack ER; Gurney H; Song Y; Perini RF; Rodriguez-Lopez K; Rini BI
Future Oncol; 2023 Dec; 19(40):2631-2640. PubMed ID: 37882432
[TBL] [Abstract] [Full Text] [Related]
19. Expanding "Practice-Changing" Belzutifan's Reach in RCC.
Cancer Discov; 2023 Dec; 13(12):OF5. PubMed ID: 37870972
[TBL] [Abstract] [Full Text] [Related]
20. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With vegfr TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
[Next]
